These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15450416)

  • 21. Single nucleotide polymorphism-based validation of exonic splicing enhancers.
    Fairbrother WG; Holste D; Burge CB; Sharp PA
    PLoS Biol; 2004 Sep; 2(9):E268. PubMed ID: 15340491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
    Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
    Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methylation and repeats in silent and nonsense mutations of p53.
    Kouidou S; Malousi A; Maglaveras N
    Mutat Res; 2006 Jul; 599(1-2):167-77. PubMed ID: 16620878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unclassified variants identified in BRCA1 exon 11: Consequences on splicing.
    Anczuków O; Buisson M; Salles MJ; Triboulet S; Longy M; Lidereau R; Sinilnikova OM; Mazoyer S
    Genes Chromosomes Cancer; 2008 May; 47(5):418-26. PubMed ID: 18273839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant splicing induced by missense mutations in BRCA1: clues from a humanized mouse model.
    Yang Y; Swaminathan S; Martin BK; Sharan SK
    Hum Mol Genet; 2003 Sep; 12(17):2121-31. PubMed ID: 12915465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PLP1 alternative splicing in differentiating oligodendrocytes: characterization of an exonic splicing enhancer.
    Wang E; Huang Z; Hobson GM; Dimova N; Sperle K; McCullough A; Cambi F
    J Cell Biochem; 2006 Apr; 97(5):999-1016. PubMed ID: 16288477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides.
    Aartsma-Rus A; Janson AA; Heemskerk JA; De Winter CL; Van Ommen GJ; Van Deutekom JC
    Ann N Y Acad Sci; 2006 Oct; 1082():74-6. PubMed ID: 17145928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous assessment of the effects of exonic mutations on RNA splicing and protein functions.
    Ho PY; Huang MZ; Fwu VT; Lin SC; Hsiao KJ; Su TS
    Biochem Biophys Res Commun; 2008 Sep; 373(4):515-20. PubMed ID: 18590700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alport syndrome. Molecular genetic aspects.
    Hertz JM
    Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The strength of the HIV-1 3' splice sites affects Rev function.
    Kammler S; Otte M; Hauber I; Kjems J; Hauber J; Schaal H
    Retrovirology; 2006 Dec; 3():89. PubMed ID: 17144911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of the Usage of Splice-Associated cis-Motifs Predict the Distribution of Human Pathogenic SNPs.
    Wu X; Hurst LD
    Mol Biol Evol; 2016 Feb; 33(2):518-29. PubMed ID: 26545919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of purine-rich exonic splicing enhancers in nuclear retention of pre-mRNAs.
    Taniguchi I; Masuyama K; Ohno M
    Proc Natl Acad Sci U S A; 2007 Aug; 104(34):13684-9. PubMed ID: 17699631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements.
    Disset A; Bourgeois CF; Benmalek N; Claustres M; Stevenin J; Tuffery-Giraud S
    Hum Mol Genet; 2006 Mar; 15(6):999-1013. PubMed ID: 16461336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synonymous SNPs provide evidence for selective constraint on human exonic splicing enhancers.
    Carlini DB; Genut JE
    J Mol Evol; 2006 Jan; 62(1):89-98. PubMed ID: 16320116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hereditary angioedema: the mutation spectrum of SERPING1/C1NH in a large Spanish cohort.
    Roche O; Blanch A; Duponchel C; Fontán G; Tosi M; López-Trascasa M
    Hum Mutat; 2005 Aug; 26(2):135-44. PubMed ID: 15971231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.
    Petitjean A; Achatz MI; Borresen-Dale AL; Hainaut P; Olivier M
    Oncogene; 2007 Apr; 26(15):2157-65. PubMed ID: 17401424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for the function of an exonic splicing enhancer after the first catalytic step of pre-mRNA splicing.
    Chew SL; Liu HX; Mayeda A; Krainer AR
    Proc Natl Acad Sci U S A; 1999 Sep; 96(19):10655-60. PubMed ID: 10485881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines.
    Liu Y; Bodmer WF
    Proc Natl Acad Sci U S A; 2006 Jan; 103(4):976-81. PubMed ID: 16418264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5' splice-site disruption.
    Wimmer K; Roca X; Beiglböck H; Callens T; Etzler J; Rao AR; Krainer AR; Fonatsch C; Messiaen L
    Hum Mutat; 2007 Jun; 28(6):599-612. PubMed ID: 17311297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
    Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
    Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.